EBITDA: Income before interest, taxes, depreciation and amortization.
LAVA Therapeutics N.V. (LVTX) had EBITDA of $-8.04M for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
-- |
|
$-3.48M |
|
-- |
|
-- |
|
$7.59M |
|
$-7.59M |
|
$4.33M |
|
$-3.25M |
|
$-3.25M |
|
$-3.48M |
|
$-3.48M |
|
$-3.48M |
|
$-3.48M |
|
$-7.59M |
|
|
EBITDA |
$-8.04M |
26.89M |
|
26.89M |
|
$-0.13 |
|
$-0.13 |
|
| Balance Sheet Financials | |
$69.78M |
|
$0.93M |
|
$1.38M |
|
$71.16M |
|
$10.37M |
|
-- |
|
$35.01M |
|
$45.37M |
|
$25.78M |
|
$25.78M |
|
$25.78M |
|
26.30M |
|
| Cash Flow Statement Financials | |
$-11.64M |
|
$15.16M |
|
-- |
|
$35.02M |
|
$39.67M |
|
$4.66M |
|
$0.54M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
6.73 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-11.64M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-13.49% |
|
-13.49% |
|
-4.89% |
|
-13.49% |
|
$0.98 |
|
$-0.43 |
|
$-0.43 |
|